Trial Profile
To evaluate the effect of Dabigatran on patients with Atrial fibrillation taking Selective serotonin reuptake inhibitor/Serotonin–norepinephrine reuptake inhibitor
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Apr 2017
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Therapeutic Use
- 08 Apr 2017 New trial record